821
Views
5
CrossRef citations to date
0
Altmetric
Commentary

The impact of patent eligibility on biotech patents: A flow chart for determining patent eligibility and an immune therapy case study

&
Pages 789-794 | Received 02 Dec 2014, Accepted 18 Dec 2014, Published online: 03 Apr 2015

References

  • Pressman D. Patent it yourself, ed. t. edition. 2000, Berkeley, CA: Nolo.com.
  • Schechter RE, Thmoas JR. Principles of Patent Law. 2004, St. Paul: West, a Thmoson business
  • Diamond v. Chakrabarty. 1980 The US Supreme Court.
  • Durham A. Patent Law Essentials. 1999, Westport: CT Greenwood Publishing Group, Inc.
  • Bilski v. Kappos. 2010 The US Supreme Court.
  • Mayo v. Prometheus. 2012, The US Supreme Court.
  • Association for Molecular Pathology v. Myriad Genetics. 2013, The US Supreme Court.
  • CLS Bank International v. Alice Corporation Pty. Ltd. 2013, Federal Circuit Court of Appeals.
  • Parker v. Flook 1978 The US Supreme Court.
  • Faber RC. Landis on mechanics of patent claim drafting. fourth edition ed.; 2001 New York: PLI Press.
  • In re Fisher. 2005, the United States Court of Appeals for the Federal Circuit.
  • Funk Brothers Seed Co. v. Kalo Inculant Co. 1948, The US Supreme Court.
  • Adelman M, et al. Cases and Materials on Patent Law,. American casebook series. 1998, ST. Paul: West Group
  • Wang S-J. Designing around patents: a guideline. Nat Biotechnol 2008; 26(5):519–522; PMID:18464780; http://dx.doi.org/10.1038/nbt0508-519
  • Dealertrack, Inc. v. Huber. 2012 Federal Circuit Court of Appeals.
  • In re Richman. 1977 The Court of Customs and Patent Appeals
  • Gottschalk v. Benson. 1972 The US Supreme Court.
  • Diamond v. Diehr. 1981 The US Supreme Court.
  • Uhlman MA, Bing MT, Lubaroff DM. Prostate cancer vaccines in combination with additional treatment modalities. Immunol Res 2014; 59(1-3):236–242; PMID:24838261; http://dx.doi.org/10.1007/s12026-014-8532-1
  • Dawson NA, Roesch EE. Sipuleucel-T and immunotherapy in the treatment of prostate cancer. Expert Opin Biol Ther 2014; 14(5):709–719; PMID:24620782; http://dx.doi.org/10.1517/14712598.2014.896897
  • Ratner M. Myriad decision aftershocks ripple through biotech. Nate Biotechnol 2013; 31(8):663–664; PMID:23929321; http://dx.doi.org/10.1038/nbt0813-663
  • Matthijs G, Huys I, Van Overwalle G, Stoppa-Lyonnet D. The European BRCA patent oppositions and appeals: coloring inside the lines. Nat Biotechnol 2013; 31(8):704–710; PMID:23929344; http://dx.doi.org/10.1038/nbt.2644

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.